α-defensin 1-3 and α-defensin 4 as predictive markers of imatinib resistance and relapse in CML patients. - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Disease Markers Année : 2011

α-defensin 1-3 and α-defensin 4 as predictive markers of imatinib resistance and relapse in CML patients.

Résumé

Imatinib mesylate is a tyrosine kinase inhibitor used as first line treatment in chronic myeloid leukaemia. Despite a remarkable effectiveness, treatment failure cases have been reported in 20 percent of CML patients. The identification of biomarkers which can predict the response to imatinib is our point of interest.

Domaines

Cancer
Fichier principal
Vignette du fichier
DM30-05-287690(1) (1).pdf (291.22 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03155364 , version 1 (01-03-2021)

Identifiants

Citer

Gabriel Etienne, Maryse Dupouy, Patricia Costaglioli, Claudine Chollet, Valérie Lagarde, et al.. α-defensin 1-3 and α-defensin 4 as predictive markers of imatinib resistance and relapse in CML patients.. Disease Markers, 2011, 30 (5), pp.221-7. ⟨10.3233/DMA-2011-0777⟩. ⟨hal-03155364⟩

Collections

CNRS
8 Consultations
23 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More